Drugs / Investigational Influenza Vaccine 1
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05827926 Comparator | Apr 2023 → Dec 2024 | COVID-19, influenza | ModernaTX, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Investigational Influenza Vaccine 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05827926 ↗ |
| Modality | Vaccine | “Participants will receive single IM injection of Investigational Influenza Vaccine 1 on Day 1.” NCT05827926 ↗ |
| Route | Intramuscular | “single IM injection” NCT05827926 ↗ |